Benralizumab is a new drug being developed for the treatment of chronic obstructive pulmonary disease. It is administered by injection under the skin and acts by targeting specific proteins that
causes the airway to narrow. If benralizumab is licensed for use in the UK, it could be a new treatment option for patients with chronic obstructive pulmonary disease that may improve quality of life and reduce the number of exacerbations.
Benralizumab for Chronic Obstructive Pulmonary Disease (COPD)
Interventions:
Benralizumab (Fasenra; MEDI563)
Indications:
Chronic obstructive pulmonary disease (COPD)
Therapeutic Areas:
Respiratory System
Year:
2017